REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
34
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Singulera Therapeutics Inc.

Collaborators